Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Post-Mkt 08-25 19:36:01 EDT

5.60

+0.04

+0.72%

盘后5.61

+0.01+0.18%

19:30 EDT

High5.72	Low5.52	Vol1.61M
Open5.69	D1 Closing5.56	Amplitude3.60%
Mkt Cap1.15B	Tradable Cap1.11B	Total Shares204.66M
T/O9.01M	T/O Rate0.81%	Tradable Shares198.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":5.6,"timestamp":1787688000000,"preClose":5.56,"halted":0,"volume":1608566,"hourTrading":{"tag":"盘后","latestPrice":5.61,"preClose":5.6,"latestTime":"19:30 EDT","volume":36093,"amount":202127.06213550002,"timestamp":1787700601814,"change":0.01,"changeRate":0.001786,"amplitude":0.026732},"delay":0,"changeRate":0.007194244604316554,"floatShares":198198210,"shares":204657499,"eps":-0.578152,"marketStatus":"Post-Mkt","change":0.04,"latestTime":"08-25 19:36:01 EDT","open":5.69,"high":5.72,"low":5.52,"amount":9011965.277943999,"amplitude":0.035971,"askPrice":6.24,"askSize":100,"bidPrice":5.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.578152,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.56,"preHourTrading":{"tag":"盘前","latestPrice":5.7,"preClose":5.56,"latestTime":"09:25 EDT","volume":591,"amount":3355.659585,"timestamp":1787664318265,"change":0.14,"changeRate":0.02518,"amplitude":0.025773},"postHourTrading":{"tag":"盘后","latestPrice":5.61,"preClose":5.6,"latestTime":"19:30 EDT","volume":36093,"amount":202127.06213550002,"timestamp":1787700601814,"change":0.01,"changeRate":0.001786,"amplitude":0.026732},"volumeRatio":0.828332,"impliedVol":1.9523,"impliedVolPercentile":0.7171},"requestUrl":"/m/hq/s/SVRA/tweets","defaultTab":"tweets","newsList":[{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4139","NVIB","BBC","GDOC","PSIL","SVRA","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662866206","title":"Savara to Present Phase 3 Impala-2 Molgramostim Data in Autoimmune Pulmonary Alveolar Proteinosis at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662866206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662866206?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:06","pubTimestamp":1787601962,"startTime":"0","endTime":"0","summary":"Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026Savara flagged new Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9Sx06R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205046","title":"Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205046?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:05","pubTimestamp":1787601900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7PWJJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661234716","title":"Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234716","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234716?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:05","pubTimestamp":1787256320,"startTime":"0","endTime":"0","summary":"Savara grants new hires options for 74,500 shares at $5.37, RSUs for 64,500 sharesSavara granted inducement equity awards on Aug. 17, 2026 to eight newly hired employees.Awards include stock options f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLcZbQC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794531","title":"Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794531?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:40","pubTimestamp":1786480802,"startTime":"0","endTime":"0","summary":"Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVISavara Inc. menyoroti kandidat utama MOLBREEVI (molgramostim inhalation solution) ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8DcjMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842945","title":"Savara Q2 EPS $(0.16) Misses $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842945","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658842945?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:36","pubTimestamp":1786480619,"startTime":"0","endTime":"0","summary":"Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128259/savara-q2-eps-0-16-misses-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Savara Q2 EPS $(0.16) Misses $(0.14) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943230","title":"Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943230","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943230?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:29","pubTimestamp":1786480184,"startTime":"0","endTime":"0","summary":"Savara Inc. reports results for the quarter ended June 30 - Earnings SummarySavara Inc.SVRA.OQreported a quarterly adjusted loss of 16 cents per share for the quarter ended June 30, lower than the sam","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44823B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658801943","title":"Savara Q2 Loss Widens as Operating Expenses Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658801943","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658801943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:13","pubTimestamp":1786479231,"startTime":"0","endTime":"0","summary":"Savara Q2 loss widens as operating expenses riseOverviewUS rare respiratory drug developer's Q2 net loss widened from prior yearOperating expenses rose, driven by higher personnel costs and commercial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BFXG1179.USD","LU2360032135.SGD","LU1585245621.USD","LU2596442595.SGD","LU2125154778.USD","LU0985481810.HKD","LU1670710661.SGD","BK4559","IHE","LU0225771236.USD","LU1670710588.SGD","LU1868836591.USD","LU1323610961.USD","LU1093756168.USD","LU2242646821.SGD","IE0002141913.USD","LU0061475181.USD","LU2133065610.SGD","LU0868494617.USD","BK4007","LU1670711040.USD","BK4532","IE00BJJMRZ35.SGD","FTXH","LU1883839398.USD","LU2242652126.USD","NGNE","LU0432979614.USD","LU0882574055.USD","LU1868837136.USD","BMY","LU1261432733.SGD","LU0306806265.USD","LU0237698245.USD","LU1868836914.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU0321505439.SGD","LU1868837300.USD","LU1989771016.USD","SVRA","LU1093756325.SGD","LU1670711123.USD","IE0009355771.USD","TARA","LU1868836757.USD","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948298","title":"Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948298","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948298?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:08","pubTimestamp":1786478900,"startTime":"0","endTime":"0","summary":"Savara rugi bersih Q2 FY26 melebar 32,3% ke USD 40,2 jutaSavara Inc. mencatat rugi bersih kuartal II 2026 melebar menjadi USD 40,2 juta, setara rugi per saham USD 0,16.Beban R&D naik 5,8% menjadi USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7PNStd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948117","title":"Savara Q2 Net Income USD -40.228 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948117","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948117?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:06","pubTimestamp":1786478761,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Q2 Net Income USD -40.228 MillionAug 11 (Reuters) - Savara Q2 operating expenses USD 40.965 million.Q2 income from operations USD -40.965 millionQ2 EPS USD -0.16","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945640","title":"Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945640?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658456589","title":"Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2658456589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658456589?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870836","title":"Savara announces EPO granted a patent covering formulation of Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870836","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655870836?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:38","pubTimestamp":1785415135,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that the European Patent Office, EPO, has granted a patent covering the liquid formulation of Molbreevi, an orally inhaled ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-epo-granted-a-patent-covering-formulation-of-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-epo-granted-a-patent-covering-formulation-of-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA","BK4139","USRD","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872497","title":"Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872497?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:11","pubTimestamp":1785413512,"startTime":"0","endTime":"0","summary":"Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041Savara secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending prot","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL1VH4r0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655547872","title":"Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of Molbreevi*, Providing Protection in Europe and Australia Until March 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2655547872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655547872?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:05","pubTimestamp":1785413100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA9YN7FM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651671514","title":"Savara Posts Corporate Presentation Focused on Autoimmune Pulmonary Alveolar Proteinosis and Molbreevi Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651671514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651671514?lang=en_us&edition=fundamental","pubTime":"2026-07-16 00:52","pubTimestamp":1784134375,"startTime":"0","endTime":"0","summary":"Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI programSavara outlined Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim inhalation solution) in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL8yLgV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558911","title":"Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558911?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819065,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directorsPalvella Therapeutics appointed Matt Pauls to its board as it prepares for a potential US launch of QTORIN rapamycin.Pauls is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9zc8Wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","PVLA","XERS","BK4112","LU2095319765.USD","BK4139","BK4007","SG9999014039.USD","SG9999014021.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SVRA","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647049643","title":"Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647049643","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647049643?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:15","pubTimestamp":1782760546,"startTime":"0","endTime":"0","summary":"Recently, Savara announced that the US FDA accepted its biologics license application for MOLBREEVI for autoimmune pulmonary alveolar proteinosis, assigning a PDUFA target action date of November 22, while CFO David Lowrance exercised 580,187 stock options and sold 394,528 shares.\nThis regulatory milestone and executive share activity highlight both the advancing path toward a potential first-in-class therapy and how insiders are managing their equity exposure at a key moment for the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/does-fda-review-of-molbreevi-and-insider-sales-shift-the-bul","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/does-fda-review-of-molbreevi-and-insider-sales-shift-the-bul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SVRA","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647104323","title":"Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647104323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647104323?lang=en_us&edition=fundamental","pubTime":"2026-06-28 23:09","pubTimestamp":1782659385,"startTime":"0","endTime":"0","summary":"Savara (SVRA) has been drawing attention after a recent stretch of strong share price performance, with the stock up about 13% over the past month and roughly 17% over the past 3 months.\nSee our latest analysis for Savara.\nAt a share price of $5.90, Savara’s recent momentum, including a 7 day share price return of 7.27% and 30 day share price return of 13.46%, sits alongside a very strong 1 year total shareholder return of 166.97%. This suggests recent gains are part of a longer trend in how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/is-savara-svra-expensive-as-its-rally-puts-a-premium-on-book","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/is-savara-svra-expensive-as-its-rally-puts-a-premium-on-book","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645006381","title":"Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645006381","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645006381?lang=en_us&edition=fundamental","pubTime":"2026-06-23 08:18","pubTimestamp":1782173921,"startTime":"0","endTime":"0","summary":"Savara CFO David L. Lowrance reported a net sale of 394,528 common shares on June 22, 2026 at USD 5.68.He exercised stock options and acquired 580,187 shares in multiple tranches at USD 1.11 to USD 4.45 per share.He disposed of 185,659 shares to cover taxes at USD 5.5 per share.He ended the day with 536,032 shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL1lDC68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com","stockEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0817},{"period":"6month","weight":-0.0479},{"period":"1year","weight":0.7595},{"period":"ytd","weight":-0.0779}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.103891},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.038506},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.017596},{"month":4,"riseRate":0.571429,"avgChangeRate":0.029792},{"month":5,"riseRate":0.642857,"avgChangeRate":0.021325},{"month":6,"riseRate":0.5,"avgChangeRate":-0.018175},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.03016},{"month":8,"riseRate":0.571429,"avgChangeRate":0.016404},{"month":9,"riseRate":0.538462,"avgChangeRate":0.011115},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.136764},{"month":11,"riseRate":0.538462,"avgChangeRate":0.131385},{"month":12,"riseRate":0.538462,"avgChangeRate":0.21983}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}